Returning guest, Dr. Andrew Cutler, Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and CEO of Florida Clinical Research Center, LLC discusses real-world data from the START study demonstrating favorable efficacy and adherence among people living with TD who used a 4-week titration kit to reach optimal dosing with AUSTEDO ® (deutetrabenazine).
Andrew J. Cutler, MD
Clinical Associate Professor of Psychiatry SUNY Upstate Medical University Syracuse, New York
CEO, Florida Clinical Research Center, LLC Bradenton, Florida
Andrew J. Cutler, MD is the Chief Medical Officer at Neuroscience Education Institute in Carlsbad, CA and a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, NY. He works remotely from Lakewood Ranch, Florida. He holds a BS in Biology from Haverford College, and obtained his medical degree from the University of Virginia School of Medicine, where he was elected into the Alpha Omega Alpha (AOA) honor medical society. Dr Cutler completed his medical internship and residencies in both Internal Medicine and Psychiatry at the University of Virginia Health Sciences Center, where he also did research training in dopamine receptor pharmacology. He is board certified in Internal Medicine by the American Board of Internal Medicine and in Psychiatry by the American Board of Psychiatry and Neurology. He is also a Certified Physician Investigator (CPI) from the Association of Clinical Research Professionals (ACRP).
Dr. Cutler has been conducting clinical research since 1993, and has been a Principal Investigator on over 400 clinical trials in a variety of CNS and medical indications, focusing on ADHD, Bipolar Disorder, Depression and Schizophrenia in children, adolescents and adults. He was an Assistant Professor of Psychiatry at the University of Chicago before moving to Florida and founding Florida Clinical Research Center (FCRC) in 1998. He sold FCRC to Meridien Research in 2016. He retired from Meridien as Executive VP and Chief Medical Officer in 2019. He has authored more than 100 peer-reviewed scientific articles and has presented more than 300 abstracts and posters at scientific meetings around the world. He is a peer reviewer for several prominent medical journals and has served on several editorial boards. He has chaired or attended over 250 medical and scientific advisory boards, delivered more than 3,000national and international pharmaceutical promotional talks, and over 300 continuing medical education(CME) and Grand rounds presentations. He has participated in more than 50 national satellite TV medical education broadcasts and led 200-plus national medical web conferences. Dr. Cutler consults extensively with pharmaceutical and biotechnology companies and serves on the board of the Neuroscience Education Institute.
Dr. Cutler is a member of the American Psychiatric Association (APA), the Florida Psychiatric Society(FPS) and the American Medical Association (AMA). He is honored to be a Fellow of both the APA and the Academy of Psychosomatic Medicine. He has received many professional honors and awards, including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the APA, the Outstanding Congressional Fellow Award from the 103rd US Congress, a citation from Florida Hospital for outstanding patient care, and the Distinguished Clinical Professional Award from the Central Florida Mental Health Associates.